Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial - Beyer-Westendorf, J; Schellong, S M; Gerlach, H (Lancet Haematol, 2017)